K-679: A Novel Antibody Drug-loaded Unimicelle Conjugate with Ultra-High Drug Loading Capacity Demonstrates Superior Efficacy in EGFR-Expressing Solid Tumors

NAGOYA, Japan , April 21, 2025 /PRNewswire/ -- Kowa Company, Ltd. (Headquarters: Nagoya, Aichi Prefecture, Japan ), today announced an upcoming presentation of non-clinical data for K-679, its novel antibody drug-loaded unimicelle conjugate (ADUC) with unprecedented drug loading capacity. The compound, developed using Kowa's proprietary micelle technology, has demonstrated superior efficacy in EGFR-expressing solid tumors compared to conventional antibody drug conjugates (ADCs).

The data will be presented at The American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25th-30th, 2025 in Chicago, Illinois . Presentation Details Presentation Title: K-679: A novel, ultra-high-DAR antibody drug-loaded unimicelle conjugate (ADUC) enabling more effective treatment in EGFR-expressing solid tumors compared to general ADCs. Session Title: Novel Drug Delivery Technologies Presentation Date and Time: April 28, 2025 , 9:00 a.



m. – 12:00 p.m.

CST ( 10:00 a.m. – 1:00 p.

m. ET ) Published Abstract Number: 1798 Presenter: Hideo Yoshida The abstract of the presentation is available at https://www.abstractsonline.

com/pp8/#!/20273/presentation/3006 . More information about the AACR Annual Meeting 2025 can be found on the event website at the following link: AACR Annual Meeting 2025 | Meetings | AACR About K- 679 K-679 is an Antibody Drug-loaded Unimicelle Conjugate (ADUC), a novel type of ADC using Kowa's proprietary micelle technology, currently at non-clinical stage. The conjugate combines an anti-EGFR antibody with drug (DM1)-loaded unimicelles, which incorporate substantial quantities of payloads into a single-chain polymer.

This innovative approach achieves an ultra-high DAR (Drug-to-Antibody Ratio) of approximately 40 DM1 molecules per antibody, significantly higher than conventional ADCs. In non-clinical studies, K-679 has demonstrated potent anti-tumor effects in xenograft models, outperforming conventional ADCs. Notably, K-679 has shown remarkable efficacy in EGFR‐positive and -negative heterogeneous tumors, exhibiting significant bystander killing effects.

Media Contact: Ian Mehr Kowa Research Institute, Inc. 919-433-1600 [email protected] Logo - https://mma.prnewswire.

com/media/320297/kowa_research_institute_inc_logo.jpg.